<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20250305215014&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;ff=20250305215014&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 06 Mar 2025 02:50:16 +0000</lastbuilddate>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0410. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042967</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0410>10.1001/jamacardio.2025.0410</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042967</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael J Blaha</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy</dc:title>
<dc:identifier>pmid:40042967</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0410</dc:identifier>
</item>
<item>
<title>Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To validate the Prognostic Models for Mortality and Morbidity in HFpEF (PREDICT-HFpEF) in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) and to evaluate the effect of finerenone, compared with placebo, across the spectrum of risk in these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The FINEARTS-HF trial was conducted across 653 sites in 37 countries. Participants were adults 40 years and older with symptomatic HF and left ventricular EF of 40% or greater randomized between September 2020 and January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The 3 PREDICT-HFpEF risk scores for the composite outcome of cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death, respectively, were calculated. Predicted risk was compared with observed outcomes. Model performance was assessed using the Harrell C statistic. The rates of the predicted outcomes (plus the composite of cardiovascular death and worsening HF events, which was the primary end point in the trial) were examined according to quintiles of risk score, as was the effect of finerenone according to risk quintiles.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6001 patients (mean [SD] age, 72 [9.6] years; 3269 male [54.5%]) were randomized in the FINEARTS-HF trial. The C statistics for cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death at 2 years were 0.71 (95% CI, 0.69-0.72), 0.68 (95% CI, 0.66-0.71), and 0.69 (95% CI, 0.67-0.71), respectively. The risk of the composite outcomes was approximately 8- to 10-fold higher in those in the highest compared with the lowest risk quintile. The relative risk reduction with finerenone compared with placebo was consistent across the spectrum of risk for all outcomes examined (eg, interaction P value for primary outcome = .24).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042880</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0025>10.1001/jamacardio.2025.0025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042880</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Kirsty McDowell</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Ross T Campbell</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Lucas Hofmeister</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF</dc:title>
<dc:identifier>pmid:40042880</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0025</dc:identifier>
</item>
<item>
<title>Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042835/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0038. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042835</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0038>10.1001/jamacardio.2025.0038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042835</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:40042835</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0038</dc:identifier>
</item>
<item>
<title>Importance of Age and Sex in Carotid Artery Plaque Detection and Cardiovascular Disease Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: CAP becomes very common with increasing age among individuals without clinical ASCVD, and the association of CAP with incident ASCVD events was strongest in younger ages, especially among women. These data can help guide ASCVD risk assessment in younger adults and provide perspective when CAP is detected on clinical imaging studies in older adults.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2024.5702. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Carotid artery plaque (CAP) is commonly encountered in clinical practice. Presence of CAP predicts future atherosclerotic cardiovascular disease (ASCVD) events; however, CAP prevalence increases with age, and it is unknown how age and sex affect the association of CAP presence and ASCVD risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To describe CAP prevalence by age, sex, race, and ethnicity in a multiethnic population and to investigate whether the impact of CAP detection on relative ASCVD risk declines with age and differs by sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study examines participants in the Multi-Ethnic Study of Atherosclerosis (MESA). Adults aged 45 to 84 years who were free of clinical ASCVD at recruitment (2000-2002) were included, and follow-up for ASCVD events was conducted through December 2019. Data analysis was performed from July 2023 to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Presence of CAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was ASCVD events (coronary heart disease events, stroke, and ASCVD death). Prevalence of CAP by age, sex, race, and ethnicity was calculated. Cox proportional hazards models with age interaction terms were used to investigate associations of CAP and incident ASCVD events across sexes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6814 adults in the MESA cohort, 5689 participants had complete data and were included in this analysis. Among these 5689 participants, mean (SD) age was 62.0 (10.2) years, and 3002 participants (53%) were female. The cohort included 1551 Black participants (27%), 687 Chinese participants (12%), 1276 Hispanic participants (22%), and 2165 White participants (38%). In total, participants experienced 1043 ASCVD events over a median (IQR) period of 17.6 (10.5-18.4) years. Prevalence of CAP differed by age, sex, race, and ethnicity, ranging from 15% in Chinese women younger than 50 years to 95% in non-Hispanic White men aged 80 to 84 years. CAP independently predicted ASCVD events (hazard ratio, 1.38; 95% CI, 1.20-1.58; P &lt; .001). The strength of this association was stronger among younger participants (≤60 years) vs older (>;60 years) (P for interaction = .01), especially among women (P for interaction = .005) vs men (P for interaction = .66). CAP detection in younger individuals conferred higher relative ASCVD risk than in older participants, who had higher absolute risk regardless of CAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: CAP becomes very common with increasing age among individuals without clinical ASCVD, and the association of CAP with incident ASCVD events was strongest in younger ages, especially among women. These data can help guide ASCVD risk assessment in younger adults and provide perspective when CAP is detected on clinical imaging studies in older adults.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042830</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5702>10.1001/jamacardio.2024.5702</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042830</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew C Tattersall</dc:creator>
<dc:creator>Spencer L Hansen</dc:creator>
<dc:creator>Robyn L McClelland</dc:creator>
<dc:creator>Claudia E Korcarz</dc:creator>
<dc:creator>Kristin M Hansen</dc:creator>
<dc:creator>Wendy S Post</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>James H Stein</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Importance of Age and Sex in Carotid Artery Plaque Detection and Cardiovascular Disease Risk</dc:title>
<dc:identifier>pmid:40042830</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5702</dc:identifier>
</item>
<item>
<title>Error in Abstract and Visual Abstract</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2025.0396. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042829</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0396>10.1001/jamacardio.2025.0396</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042829</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Abstract and Visual Abstract</dc:title>
<dc:identifier>pmid:40042829</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0396</dc:identifier>
</item>
<item>
<title>Coronary Artery Calcium Testing-Too Early, Too Late, Too Often</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: These clinical scenarios reflect when consideration of CAC score is of use and when it is not. Although CAC testing is becoming more widely available and sought after by clinicians and patients alike, it is only as useful as the clinical context. Understanding when assessing CAC score is too early to effectively rule out risk, too late to influence decisions, or too often to yield clinically relevant information provides important insights that optimize the clinical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2024.5644. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Traditional risk factors, enhancing factors, and risk scores help clinicians assess atherosclerotic cardiovascular disease (ASCVD) risk for primary prevention. The latest cholesterol guidelines suggest measuring coronary artery calcium (CAC) score by computed tomography (CT) in those at intermediate risk when there is uncertainty about statin initiation for primary prevention. CAC testing can improve both risk estimation and adherence to cardiovascular risk-reducing behaviors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: As measuring CAC score has become more widely available, this article focuses on 3 situations where CAC testing may be omitted or deferred until a time when CAC testing can provide clinically useful information. Three clinical scenarios to facilitate the clinician-patient risk discussion are as follows: (1) when CAC testing is too early, (2) when CAC testing is too late, and (3) when CAC testing is repeated too often. The timing of CAC testing sits within the decision point of lipid-lowering therapy use. High-risk young adults may face an elevated lifetime risk of cardiovascular disease despite a CAC level of 0, whereas older adults may not see an expected benefit over a short time horizon or may already be taking lipid-lowering therapy, rendering a CAC score less valuable. Integrating a CAC score into the decision to initiate lipid-lowering therapy requires understanding of a patient's risk factors, including age, as well as the natural history of atherosclerosis and related events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: These clinical scenarios reflect when consideration of CAC score is of use and when it is not. Although CAC testing is becoming more widely available and sought after by clinicians and patients alike, it is only as useful as the clinical context. Understanding when assessing CAC score is too early to effectively rule out risk, too late to influence decisions, or too often to yield clinically relevant information provides important insights that optimize the clinical utility of this potentially valuable prognostic tool.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042828</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5644>10.1001/jamacardio.2024.5644</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042828</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexander R Zheutlin</dc:creator>
<dc:creator>Anuj K Chokshi</dc:creator>
<dc:creator>John T Wilkins</dc:creator>
<dc:creator>Neil J Stone</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Coronary Artery Calcium Testing-Too Early, Too Late, Too Often</dc:title>
<dc:identifier>pmid:40042828</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5644</dc:identifier>
</item>
<item>
<title>Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40042824/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: These findings enhance mechanistic insights into the effect of valsartan in early-stage HCM, showing potential benefits on biventricular remodeling and myocardial intracellular volume. Further research to identify cellular mechanisms of valsartan on HCM progression is needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 5. doi: 10.1001/jamacardio.2024.5677. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights, but whether valsartan influences these parameters remains uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the treatment effects of valsartan on myocardial structure, function, and tissue parameters in early-stage sarcomeric HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prespecified CMR substudy of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) randomized clinical trial evaluated treatment effects of valsartan vs placebo on myocardial structure, function, and tissue parameters and was conducted from April 2014 through July 2019 at 17 international sites. Individuals aged 8 to 45 years with early-stage HCM aged between 8 and 45 years and with no or minimal symptoms were eligible for inclusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Treatment with placebo or valsartan (80 mg per day for children weighing &lt;35 kg, 160 mg per day for children weighing ≥35 kg, or 320 mg per day for adults aged 18 years or older).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was mean change in CMR parameters between baseline and year 2, including indexed extracellular volume (iECV), indexed intracellular volume (iICV), and late gadolinium enhancement (LGE). Mean between-group differences in CMR parameters between baseline and year 2 were evaluated using multivariable mixed-effects linear regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 137 of 178 VANISH participants (77.0%) underwent CMR imaging at baseline and year 2. Among these participants, mean (SD) age was 23 (10) years, and 51 participants (37.2%) were female. Baseline characteristics and CMR parameters were well balanced between treatment groups. Higher LGE, iECV, and iICV at baseline were associated with higher cardiac biomarker levels and more pronounced cardiac remodeling. Between baseline and year 2, valsartan appeared to increase left ventricular (LV) end-diastolic volume index (mean difference [MD], 3.3 mL/m2; 95% CI, 0.4-6.2; P = .03), suggesting treatment benefit, but did not significantly impact LV mass index (MD, -2.9 g/m2; 95% CI, -6.1 to 0.2; P = .07) or LV ejection fraction. Similarly, valsartan appeared to reduce decline in right ventricular volumes. Valsartan appeared to significantly reduce iICV progression (MD, -5.0 mL/m2; 95% CI, -9.7 to -0.4; P = .03), but did not impact iECV (MD, 0.0 mL/m2; 95% CI, -1.4 to 1.3; P = .95) or LGE progression (MD, 0.5%; 95% CI, -0.4 to 1.3; P = .30).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: These findings enhance mechanistic insights into the effect of valsartan in early-stage HCM, showing potential benefits on biventricular remodeling and myocardial intracellular volume. Further research to identify cellular mechanisms of valsartan on HCM progression is needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40042824/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40042824</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5677>10.1001/jamacardio.2024.5677</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40042824</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Michael Jerosch-Herold</dc:creator>
<dc:creator>Anna Axelsson Raja</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Kenneth Zahka</dc:creator>
<dc:creator>Alexandre C Pereira</dc:creator>
<dc:creator>Steven D Colan</dc:creator>
<dc:creator>Anne M Murphy</dc:creator>
<dc:creator>Charles Canter</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Amit R Patel</dc:creator>
<dc:creator>Ivan Wilmot</dc:creator>
<dc:creator>Jonathan H Soslow</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Jose D Vargas</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy</dc:title>
<dc:identifier>pmid:40042824</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5677</dc:identifier>
</item>
<item>
<title>A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40038847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 5:ehaf001. doi: 10.1093/eurheartj/ehaf001. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40038847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40038847</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf001>10.1093/eurheartj/ehaf001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40038847</guid>
<pubDate>Wed, 05 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Alexandra Butters</dc:creator>
<dc:creator>Kate Thomson</dc:creator>
<dc:creator>Franki Harrington</dc:creator>
<dc:creator>Natasha Henden</dc:creator>
<dc:creator>Karen McGuire</dc:creator>
<dc:creator>Alicia B Byrne</dc:creator>
<dc:creator>Samantha Bryen</dc:creator>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Megan Leask</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>John Atherton</dc:creator>
<dc:creator>Johan M Bos</dc:creator>
<dc:creator>Colleen Caleshu</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Kyla Dunn</dc:creator>
<dc:creator>Ian Hayes</dc:creator>
<dc:creator>Jimmy Juang</dc:creator>
<dc:creator>Julie McGaughran</dc:creator>
<dc:creator>Natalie Nowak</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Anne Ronan</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Jil C Tardiff</dc:creator>
<dc:creator>Marianne Tiemensma</dc:creator>
<dc:creator>Tony R Merriman</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Jonathan R Skinner</dc:creator>
<dc:creator>Daniel G MacArthur</dc:creator>
<dc:creator>Owen M Siggs</dc:creator>
<dc:creator>Richard D Bagnall</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:date>2025-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets</dc:title>
<dc:identifier>pmid:40038847</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf001</dc:identifier>
</item>
<item>
<title>Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehae931. doi: 10.1093/eurheartj/ehae931. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae931>10.1093/eurheartj/ehae931</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037651</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Dick C Chan</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies</dc:title>
<dc:identifier>pmid:40037651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae931</dc:identifier>
</item>
<item>
<title>Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093/eurheartj/ehae938. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037646</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae938>10.1093/eurheartj/ehae938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037646</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Andrew Coats</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Martina Brueckmann</dc:creator>
<dc:creator>Sibylle J Hauske</dc:creator>
<dc:creator>Elke Schueler</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial</dc:title>
<dc:identifier>pmid:40037646</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae938</dc:identifier>
</item>
<item>
<title>Gaining the upper hand on peripheral artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 4:ehaf132. doi: 10.1093/eurheartj/ehaf132. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037639</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf132>10.1093/eurheartj/ehaf132</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037639</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Francisco Ujueta</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Marie Gerhard-Herman</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gaining the upper hand on peripheral artery disease</dc:title>
<dc:identifier>pmid:40037639</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf132</dc:identifier>
</item>
<item>
<title>High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A high intensity exercise programme is feasible in patients with HCM, with apparent cardiovascular and psychological benefits, and no increase in arrhythmias. A large-scale study is required to substantiate findings and assess long-term safety of high intensity exercise in HCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3:ehae919. doi: 10.1093/eurheartj/ehae919. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The feasibility and impact of high intensity exercise programmes in patients with hypertrophic cardiomyopathy (HCM) are unknown. This study was conducted to determine the feasibility of a high intensity exercise programme and explore safety and efficacy outcomes in patients with HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants were randomized to a 12-week supervised exercise programme (n = 40) in addition to usual care, or usual care alone (n = 40). All participants underwent assessment at baseline and 12 weeks. The exercise group was re-evaluated 6 months post-programme. Feasibility was assessed by (i) recruitment, adherence, and retention rates; (ii) staffing ratios; (iii) logistics; and (iv) acceptability of the intervention. The primary exploratory safety outcome was a composite of arrhythmia-related events. Exploratory secondary outcomes included changes in (i) cardiorespiratory fitness; (ii) cardiovascular risk factors; and (iii) quality of life, anxiety, and depression scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 67 (84%) participants completed the study (n = 34 and n = 33 in the exercise and usual care groups, respectively). Reasons for non-adherence included travel, work, and family commitments. Resource provision complied with national cardiac rehabilitation standards. There was no difference between groups for the exploratory safety outcome (P = .99). At 12 weeks, the exercise group had a greater increase in peak oxygen consumption (VO2) [+4.1 mL/kg/min, 95% confidence interval (CI) 1.1, 7.1] and VO2 at anaerobic threshold (+2.3 mL/kg/min, 95% CI 0.4, 4.1), lower systolic blood pressure (-7.3 mmHg, 95% CI -11.7, -2.8) and body mass index (-0.8 kg/m2, 95% CI -1.1, -0.4), and greater improvement in hospital anxiety (-3, 95% CI -4.3, -1.7) and depression (-1.7, 95% CI -2.9, -0.5) scores, compared to the usual care group. Most exercise gains dissipated at 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A high intensity exercise programme is feasible in patients with HCM, with apparent cardiovascular and psychological benefits, and no increase in arrhythmias. A large-scale study is required to substantiate findings and assess long-term safety of high intensity exercise in HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037382</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae919>10.1093/eurheartj/ehae919</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037382</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Joyee Basu</dc:creator>
<dc:creator>Dimitra Nikoletou</dc:creator>
<dc:creator>Chris Miles</dc:creator>
<dc:creator>Hamish MacLachlan</dc:creator>
<dc:creator>Gemma Parry-Williams</dc:creator>
<dc:creator>Fred Tilby-Jones</dc:creator>
<dc:creator>Paulo Bulleros</dc:creator>
<dc:creator>Zephryn Fanton</dc:creator>
<dc:creator>Claire Baker</dc:creator>
<dc:creator>Shane Purcell</dc:creator>
<dc:creator>Carmen Lech</dc:creator>
<dc:creator>Tracy Chapman</dc:creator>
<dc:creator>Peter Sage</dc:creator>
<dc:creator>Shams Wahid</dc:creator>
<dc:creator>Nabeel Sheikh</dc:creator>
<dc:creator>Shruti Jayakumar</dc:creator>
<dc:creator>Aneil Malhotra</dc:creator>
<dc:creator>Tracey Keteepe-Arachi</dc:creator>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Gherardo Finocchiaro</dc:creator>
<dc:creator>Gerald Carr-White</dc:creator>
<dc:creator>Elijah Behr</dc:creator>
<dc:creator>Maite Tome</dc:creator>
<dc:creator>Jamie O'Driscoll</dc:creator>
<dc:creator>Irina Chis Ster</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial</dc:title>
<dc:identifier>pmid:40037382</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae919</dc:identifier>
</item>
<item>
<title>Targeted approach for next-generation coronary stents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3:ehaf007. doi: 10.1093/eurheartj/ehaf007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037368</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf007>10.1093/eurheartj/ehaf007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037368</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Simon D Brown</dc:creator>
<dc:creator>Julie Rodor</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Targeted approach for next-generation coronary stents</dc:title>
<dc:identifier>pmid:40037368</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf007</dc:identifier>
</item>
<item>
<title>Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>Bacterial immunotherapy holds promising cancer-fighting potential. However, unlocking its power requires a mechanistic understanding of how bacteria both evade antimicrobial immune defenses and stimulate anti-tumor immune responses within the tumor microenvironment (TME). Here, by harnessing an engineered Salmonella enterica strain with this dual proficiency, we unveil an underlying singular mechanism. Specifically, the hysteretic nonlinearity of interleukin-10 receptor (IL-10R) expression...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20:S0092-8674(25)00158-8. doi: 10.1016/j.cell.2025.02.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bacterial immunotherapy holds promising cancer-fighting potential. However, unlocking its power requires a mechanistic understanding of how bacteria both evade antimicrobial immune defenses and stimulate anti-tumor immune responses within the tumor microenvironment (TME). Here, by harnessing an engineered Salmonella enterica strain with this dual proficiency, we unveil an underlying singular mechanism. Specifically, the hysteretic nonlinearity of interleukin-10 receptor (IL-10R) expression drives tumor-infiltrated immune cells into a tumor-specific IL-10R<sup>hi</sup> state. Bacteria leverage this to enhance tumor-associated macrophages producing IL-10, evade phagocytosis by tumor-associated neutrophils, and coincidently expand and stimulate the preexisting exhausted tumor-resident CD8<sup>+</sup> T cells. This effective combination eliminates tumors, prevents recurrence, and inhibits metastasis across multiple tumor types. Analysis of human samples suggests that the IL-10R<sup>hi</sup> state might be a ubiquitous trait across human tumor types. Our study unveils the unsolved mechanism behind bacterial immunotherapy's dual challenge in solid tumors and provides a framework for intratumoral immunomodulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037354</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.002>10.1016/j.cell.2025.02.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037354</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Zhiguang Chang</dc:creator>
<dc:creator>Xuan Guo</dc:creator>
<dc:creator>Xuefei Li</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Zhongsheng Zang</dc:creator>
<dc:creator>Siyu Pei</dc:creator>
<dc:creator>Weiqi Lu</dc:creator>
<dc:creator>Yang Li</dc:creator>
<dc:creator>Jian-Dong Huang</dc:creator>
<dc:creator>Yichuan Xiao</dc:creator>
<dc:creator>Chenli Liu</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization</dc:title>
<dc:identifier>pmid:40037354</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.002</dc:identifier>
</item>
<item>
<title>Non-traditional risk factors and artificial intelligence in the management of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037331/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3;46(9):771-774. doi: 10.1093/eurheartj/ehaf028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037331/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037331</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf028>10.1093/eurheartj/ehaf028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037331</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-traditional risk factors and artificial intelligence in the management of atrial fibrillation</dc:title>
<dc:identifier>pmid:40037331</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf028</dc:identifier>
</item>
<item>
<title>Exercise prescription in hypertrophic cardiomyopathy: Dr Lown's lesson to break taboos</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40037289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 3:ehae659. doi: 10.1093/eurheartj/ehae659. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40037289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40037289</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae659>10.1093/eurheartj/ehae659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40037289</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Flavio D'Ascenzi</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise prescription in hypertrophic cardiomyopathy: Dr Lown's lesson to break taboos</dc:title>
<dc:identifier>pmid:40037289</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae659</dc:identifier>
</item>
<item>
<title>Mixed valvular heart disease: diagnosis and management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036874/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>Mixed valvular diseases (MVDs) are common but have received little attention in the literature, especially regarding the mitral valve (MV) and the right-sided cardiac valves. Whereas echocardiography plays a pivotal diagnostic role, the diagnosis is made difficult due to haemodynamic interactions that may invalidate common indices of severity used in isolated stenosis or regurgitation. The diagnostic strategy should aim at initially separately assessing stenosis and regurgitation, taking into...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 27:ehaf116. doi: 10.1093/eurheartj/ehaf116. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mixed valvular diseases (MVDs) are common but have received little attention in the literature, especially regarding the mitral valve (MV) and the right-sided cardiac valves. Whereas echocardiography plays a pivotal diagnostic role, the diagnosis is made difficult due to haemodynamic interactions that may invalidate common indices of severity used in isolated stenosis or regurgitation. The diagnostic strategy should aim at initially separately assessing stenosis and regurgitation, taking into account the diagnostic pitfalls, with complementary use of multimodality imaging in cases of persisting diagnostic uncertainties. Unlike aortic stenosis, the calcium score cannot be used as a surrogate for haemodynamic severity of mixed MV disease. Severe stenosis and/or severe regurgitation are indicative of severe MVD, and management should follow recommendations on the predominant lesion. However, some patients with the combination of moderate stenosis and moderate regurgitation have a poor prognosis when left untreated. Concordant data suggest that, in patients with mixed aortic or MV disease, transvalvular velocities and pressure gradients are more powerful prognostic indicators than valve area or the severity of regurgitation. It is essential to consider the global repercussions that indicate poor outcomes in patients with MVD. However, whereas symptoms and/or ventricular dysfunction are considered as clear indication for intervention, imaging cut-offs have not been validated for balanced moderate regurgitation and stenosis. Although emerging evidence tends to support earlier management, further prospective studies are required, and pending the results of these studies, asymptomatic patients with MVD should be closely monitored.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036874/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40036874</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf116>10.1093/eurheartj/ehaf116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036874</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Philippe Unger</dc:creator>
<dc:creator>Xavier Galloo</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mixed valvular heart disease: diagnosis and management</dc:title>
<dc:identifier>pmid:40036874</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf116</dc:identifier>
</item>
<item>
<title>Extracellular vesicles to mediate RNA therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036797/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf046. doi: 10.1093/eurheartj/ehaf046. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036797/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40036797</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf046>10.1093/eurheartj/ehaf046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036797</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Jes-Niels Boeckel</dc:creator>
<dc:creator>Junjie Xiao</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Extracellular vesicles to mediate RNA therapies</dc:title>
<dc:identifier>pmid:40036797</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf046</dc:identifier>
</item>
<item>
<title>Drug-coated balloons in small vessel de novo coronary artery disease: better than DES?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036794/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf083. doi: 10.1093/eurheartj/ehaf083. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036794/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40036794</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf083>10.1093/eurheartj/ehaf083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036794</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Christina Lalani</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Drug-coated balloons in small vessel de novo coronary artery disease: better than DES?</dc:title>
<dc:identifier>pmid:40036794</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf083</dc:identifier>
</item>
<item>
<title>Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>The aim of this whitepaper is to review the current state of the literature on the effects of cardio-oncology rehabilitation and exercise (CORE) programmes and provide a roadmap for improving the evidence-based to support the implementation of CORE. There is an urgent need to reinforce and extend the evidence informing the cardiovascular care of cancer survivors. CORE is an attractive model that is potentially scalable to improve the cardiovascular health of cancer survivors as it leverages many...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf100. doi: 10.1093/eurheartj/ehaf100. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The aim of this whitepaper is to review the current state of the literature on the effects of cardio-oncology rehabilitation and exercise (CORE) programmes and provide a roadmap for improving the evidence-based to support the implementation of CORE. There is an urgent need to reinforce and extend the evidence informing the cardiovascular care of cancer survivors. CORE is an attractive model that is potentially scalable to improve the cardiovascular health of cancer survivors as it leverages many of the existing frameworks developed through decades of delivery of cardiac rehabilitation. However, there are several challenges within this burgeoning field, including limited evidence of the efficacy of this approach in patients with cancer. In this paper, a multidisciplinary team of international experts highlights priorities for future research in this field and recommends standards for the conduct of research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036781/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40036781</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf100>10.1093/eurheartj/ehaf100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036781</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Scott C Adams</dc:creator>
<dc:creator>Fernando Rivera-Theurel</dc:creator>
<dc:creator>Jessica M Scott</dc:creator>
<dc:creator>Michelle B Nadler</dc:creator>
<dc:creator>Stephen Foulkes</dc:creator>
<dc:creator>Darryl Leong</dc:creator>
<dc:creator>Tormod Nilsen</dc:creator>
<dc:creator>Charles Porter</dc:creator>
<dc:creator>Mark Haykowsky</dc:creator>
<dc:creator>Husam Abdel-Qadir</dc:creator>
<dc:creator>Sarah C Hull</dc:creator>
<dc:creator>Neil M Iyengar</dc:creator>
<dc:creator>Christina M Dieli-Conwright</dc:creator>
<dc:creator>Susan F Dent</dc:creator>
<dc:creator>Erin J Howden</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group</dc:title>
<dc:identifier>pmid:40036781</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf100</dc:identifier>
</item>
<item>
<title>Loss of the Y chromosome in coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40036778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250305215014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 28:ehaf072. doi: 10.1093/eurheartj/ehaf072. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40036778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250305215014&v=2.18.0.post9+e462414">40036778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf072>10.1093/eurheartj/ehaf072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40036778</guid>
<pubDate>Tue, 04 Mar 2025 06:00:00 -0500</pubDate>
<dc:creator>Soichi Sano</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2025-03-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loss of the Y chromosome in coronary artery disease</dc:title>
<dc:identifier>pmid:40036778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf072</dc:identifier>
</item>





























</channel>
</rss>